The increasingly complex array of local and systemic immunosuppressive options available to ophthalmologists caring for patients with ocular inflammatory diseases requires thoughtful consideration of the risks and benefits associated with the introduction of each novel therapy. In this issue of the Archives, Callanan et al1 report the long-term results of a large cohort of patients with uveitis treated with the fluocinolone acetonide (FA) intravitreal implant and present their appraisal of this medication. Their study contributes greatly to our understanding of the potential benefits of this local corticosteroid delivery system, and their discussion of reported complications is critical for patient counseling and risk assessment when considering the precise role of this therapy for patient care.